|1.||Dionisio, Paolo: 5 articles (01/2009 - 01/2002)|
|2.||Cai, Tommaso: 3 articles (07/2012 - 06/2009)|
|3.||Bartoletti, R: 3 articles (01/2010 - 03/2006)|
|4.||Salvatori, Enrica: 3 articles (02/2006 - 01/2002)|
|5.||Rosignoli, M T: 2 articles (10/2013 - 01/2005)|
|6.||Dionisio, P: 2 articles (10/2013 - 01/2005)|
|7.||Wagenlehner, Florian M E: 2 articles (01/2013 - 07/2012)|
|8.||Mondaini, Nicola: 2 articles (07/2012 - 06/2009)|
|9.||Bartoletti, Riccardo: 2 articles (07/2012 - 06/2009)|
|10.||Mazzoli, Sandra: 2 articles (07/2012 - 06/2009)|
04/01/2011 - "In summary, prulifloxacin appears to be a promising agent for the treatment of bacterial prostatitis and traveller's diarrhoea."
01/01/2010 - "The purpose of this study was to compare the efficacy of a 14-day course of prulifloxacin 600 mg with standard antibiotic therapy for the treatment of chronic prostatitis due to Chlamydia trachomatis (Ct) infection. "
01/01/2010 - "Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study."
09/01/2009 - "Re: Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study."
06/01/2009 - "Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study."
07/01/2012 - "In this study treatment with FERTIMEV together with prulifloxacin improved semen parameters in patients with Ct genital infection and oligoasthenoteratozoospermia compared to treatment with prulifloxacin therapy alone."
07/01/2012 - "Semen quality in patients with Chlamydia trachomatis genital infection treated concurrently with prulifloxacin and a phytotherapeutic agent."
01/01/2010 - "Prulifloxacin was also equivalent to standard therapy for clinical success, as demonstrated by a decrease in the number of patients affected by CP due to Ct infection."
02/01/2009 - "Additional research is needed to further elucidate the promising role of prulifloxacin in the treatment of infections sustained by multidrug-resistant pathogens and to consolidate the wide spectrum of activity from a clinical standpoint."
03/01/2007 - "In patients undergoing transrectal ultrasound-guided prostate biopsy, antimicrobial prophylaxis with prulifloxacin, both in single shot and 5-day administration, was found to prevent infection, with good tolerability and acceptability by the patients."
01/01/2005 - "The findings from this lung penetration study could explain the efficacy of once-daily prulifloxacin 600mg observed in clinical trials conducted in patients with exacerbation of chronic bronchitis."
01/01/2007 - "Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis."
01/01/2006 - "Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis."
04/01/2011 - "Prulifloxacin is a fluoroquinolone antibiotic that has been approved in several European countries for the treatment of lower urinary tract infections and exacerbations of chronic bronchitis. "
01/01/2002 - "Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis."
|4.||Urinary Tract Infections (Urinary Tract Infection)
10/01/2007 - "In this study, we focused on the therapeutic efficacy of prulifloxacin (PUFX) against Pseudomonas aeruginosa OP 14-210, isolated from a patient with complicated urinary tract infection. "
04/01/2011 - "In this review, PubMed and Scopus databases were searched for potential uses of prulifloxacin beyond respiratory and urinary tract infections. "
04/01/2011 - "Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections."
06/01/2007 - "Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E. "
06/01/2007 - "In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance."
|5.||Respiratory Tract Infections (Respiratory Tract Infection)
02/01/2006 - "A number of randomized, controlled clinical trials carried out in Europe demonstrated the efficacy of prulifloxacin in the treatment of urinary tract (acute uncomplicated and complicated) and respiratory tract infections (acute exacerbations of chronic bronchitis), in comparison with the most widely used drugs such as ciprofloxacin, co-amoxiclav and pefloxacin. "
|5.||Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)
|2.||Suburethral Slings (Tension-Free Vaginal Tape)